Eight Cycles of ABVD Versus Four Cycles of BEACOPP<sub>escalated</sub>Plus Four Cycles of BEACOPP<sub>baseline</sub>in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Patrice Carde(Institut Gustave Roussy), Nicolas Mounier(Centre Hospitalier Universitaire de Nice), Serge Bologna(Centre Hospitalier Régional et Universitaire de Nancy), F. Morschhauser(Université de Lille), Ralph M. Meyer(Queen's University), Isabelle Gaillard(Erasmus Hospital), Catherine Fortpied(European Organisation for Research and Treatment of Cancer), Hussein Khaled(Centre Hospitalier Universitaire de Lille), Bengt Glimelius(Uppsala University), Olivier Casasnovas, Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Christophe Fermé(Centre Hospitalier Universitaire de Lille), Denis Caillot, Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Igor Aurer(University Hospital Centre Zagreb), Max Wolf(Peter MacCallum Cancer Centre), Matthias Karrasch(Unknown), Matthew D. Seftel(CancerCare Manitoba), Pauline Brice(Hôpital de Jolimont), Bertrand Coiffier(Unknown)
Cited by 121
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k